Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors

a technology of hydroxysteroid dehydrogenase and triazine, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of severe metabolic abnormalities, but no significant increase in plasma cortisol levels

Active Publication Date: 2007-09-06
BRISTOL MYERS SQUIBB CO
View PDF23 Cites 56 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] Compounds of the present invention inhibit the activity of the enzyme Compounds of the present invention inhibit the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I. Consequently, the compounds of the present invention may be used in the treatment of multiple diseases or disorders associated with 11-beta-hydroxysteroid dehydrogenase type I, such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, and other maladies. Examples of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I that can be prevented, inhibited, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy and glaucoma.
[0008] The present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds, and for methods of using such compounds. In particular, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier.
[0009] Further, in accordance with the present invention, a method is provided for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type I, such as defined above and hereinafter, wherein a therapeutically effective amount of a compound of formula I is administered to a mammalian, i.e., human, patient in need of treatment.

Problems solved by technology

However, an excess of cortisol, as occurs in Cushing's Disease, provokes severe metabolic abnormalities including: type 2 diabetes, cardiovascular disease, obesity, and osteoporosis.
Many patients with these diseases, however, do not show significant increases in plasma cortisol levels.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

3-Adamantan-1-yl-5,6-dimethyl-[1,2,4]triazine

[0285]

[0286] A mixture of admantane-1-carbohydrazide (0.5 mmol), 2,3-butanedione (0.6 mmol) and NH4OAc (7.5 mmol) in HOAc (glacial, 3 mL) was heated at reflux for 8 h. After this time, the reaction was cooled to room temperature and most of the HOAc was removed in vacuo to yield a residue. The residue was neutralized with sat aq Na2CO3 (5 ml) and extracted with EtOAc (3×5 ml). The combined organic layers were dried over MgSO4, filtered, and concentrated to provide the crude product. The crude product was purified by ISCO flash chromatography to provide Example 1 (45 mg). HPLC Rt (Method A): 3.79 min. LCMS: m / z 244 (M+H+). HPLC purity: 98%. 1H NMR δ 2.66(s, 3H), 2.53 (s, 3H), 1.90-2.20 (m, 9H), 1.80 (s, 6H).

example 2

3-Adamantan-1-yl-6,7,8,9-tetrahydro-5H-cyclohepta[1,2,4]triazine

[0287]

[0288] A mixture of admantane-1-carbohydrazide (0.5 mmol), cycloheptane-1,2-dione (0.6 mmol) and NH4OAc (7.5 mmol) in HOAc (glacial, 3 mL) was heated at 180° C. for 10 min in a microwave reactor. After this time, the reaction mixture was cooled to RT. Once at the prescribed temperature, most of the HOAc was removed in vacuo to yield a residue. The residue was neutralized with saturated aq Na2CO3 (5 ml) and extracted with EtOAc (3×5 ml). The combined organic layers were dried over MgSO4, filtered, and concentrated to provide the crude product. The crude product was purified by ISCO flash chromatography provide Example 2 (58 mg). HPLC RT (Method A): 4.12 min. LCMS: m / z 284 (M+H+). HPLC purity: 98%. 1H NMR (CDCl3, 400 MHz) δ 3.19 (t, J=6 Hz, 2H), 2.98 (t, J=6 Hz, 2H), 2.12 (s, 9H), 1.70-1.95 (m, 6H), 1.80 (s, 6H). 13C NMR (CDCl3, 75 MHz) δ172.6, 164.2, 159.82, 40.7, 39.7, 38.13, 36.6, 35.0, 31.9, 28.4, 26.2, 25.9. E...

examples 3 to 73

[0289] Examples 3 to 32 in the following table can be prepared according to the procedures described in Examples 1 or 2, or by other similar methods known to one skilled in the art, with other appropriate reagents.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
plasmaaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:
or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.

Description

RELATED APPLICATION [0001] This application claims the benefit of U.S. Provisional Application No. 60 / 778,159, filed on Mar. 1, 2006, incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION [0002] The steroid hormone cortisol is a key regulator of many physiological processes. However, an excess of cortisol, as occurs in Cushing's Disease, provokes severe metabolic abnormalities including: type 2 diabetes, cardiovascular disease, obesity, and osteoporosis. Many patients with these diseases, however, do not show significant increases in plasma cortisol levels. In addition to plasma cortisol, individual tissues can regulate their glucocorticoid tone via the in situ conversion of inactive cortisone to the active hormone cortisol. Indeed, the normally high plasma concentration of cortisone provides a ready supply of precursor for conversion to cortisol via the intracellular enzyme 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1). [0003] 11-beta-HSD1 is a m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/675A61K31/55A61K31/541A61K31/5377A61K31/53C07D403/02C07D413/02C07D417/02
CPCC07D253/10C07D253/07A61P3/06A61P5/46A61P9/02A61P3/10
Inventor LI, JUNROBL, JEFFREY A.KENNEDY, LAWRENCE J.
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap